Federal Register #16150116

NCI Seeks Partners for NPM1 Mutation-Specific T Cell Receptors for AML Therapy

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), seeks partners for a novel cancer immunotherapy technology: - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Technology Transfer Center - OEMs and Vendors: - No commercial OEMs or vendors are named; the technology originates from NCI - Products/Technologies Requested: - NPM1 Mutation-Specific T Cell Receptors (TCR6 and TCR7) - Part number: E20020250 - Pre-clinical stage, covered by a U.S. provisional patent - Designed for adoptive T cell therapy targeting Acute Myeloid Leukemia (AML) patients with HLAA*11:01 - Demonstrates robust, specific cytotoxicity against AML cells with minimal off-target effects - Unique/Notable Requirements: - Seeking research co-development partners or licensees for further development and commercialization - Technology is specific to AML patients expressing HLAA*11:01 and the NPM1 mutation - Opportunity is for technology transfer, not a traditional product or service procurement - Additional Administrative Notice: - USCIS (Department of Homeland Security) is extending its information collection for the Request for Fee Waiver (Form I-912), but this is not a procurement opportunity

Description

The Department of Homeland Security (DHS), U.S. Citizenship and Immigration Services (USCIS) is seeking to extend without change a currently approved information collection related to the Request for Fee Waiver (Form I-912). This collection is used to verify that applicants are unable to pay fees for immigration benefits and to streamline USCIS's review of fee waiver requests. The notice allows an additional 30 days for public comments, with comments closing on August 24, 2026. The collection involves individuals or households submitting documentation to support fee waiver requests.

View original listing